Today before the opening bell, Rainbow Coral announced that it has opened talks this week to potentially partner with an emerging innovator in the transdermal delivery sector. This move is part of the company’s drive to carve out a share of the $142 billion U.S. drug delivery market.
Transdermal patches are an increasingly popular drug delivery system that is being developed for everything from contraception to Parkinson’s disease. Transdermal drug delivery prevents many of the problems associated with oral and intravenous routes as well as offers major advantages such as improved bioavailability, more uniform plasma levels, longer duration of action, reduced side effects, and improved therapy.
Some analysts have predicted that the transdermal delivery market could be worth as much as $31.5 billion by 2015 from a value of $21.5 billion just three years ago. Rainbow Coral believes partnering with an emerging leader in the sector could help the company capture a big piece of that growth.
“Transdermal patches offer a non-invasive option for treating many diseases and disorders,” said RBCC CEO Patrick Brown. “The appeal is obvious. We’re in negotiations now with a patch developer we believe has high profit potential, and we’re optimistic that a deal can be struck soon.”
For more information, visit www.RainbowBioSciences.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment